Aurora Cannabis Reports Q1 Fiscal 2026 Results

TL;DR

ACB dropped Q1 FY26 results Aug 6, 2025. Foreign private issuer filing.

AI Summary

Aurora Cannabis Inc. announced its first quarter fiscal 2026 results on August 6, 2025. The company, led by CEO Miguel Martin, is listed on NASDAQ and TSX under the ticker ACB. This filing is a Form 6-K, indicating it's a report from a foreign private issuer.

Why It Matters

This report provides investors with an update on Aurora Cannabis's financial performance and operational status for the first quarter of fiscal year 2026.

Risk Assessment

Risk Level: low — This is a routine financial filing (6-K) that typically contains news releases or financial updates, not significant new risks.

Key Players & Entities

• Aurora Cannabis Inc. (company) — Registrant
• Miguel Martin (person) — Chief Executive Officer
• August 6, 2025 (date) — Filing Date and News Release Date
• NASDAQ | TSX: ACB (company) — Stock Ticker

FAQ

From the Filing

0001279569-25-000828.txt : 20250806 0001279569-25-000828.hdr.sgml : 20250806 20250806072142 ACCESSION NUMBER: 0001279569-25-000828 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20250806 FILED AS OF DATE: 20250806 DATE AS OF CHANGE: 20250806 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AURORA CANNABIS INC CENTRAL INDEX KEY: 0001683541 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38691 FILM NUMBER: 251187449 BUSINESS ADDRESS: STREET 1: 2207 90B STREET SW CITY: EDMONTON STATE: A0 ZIP: T6X 1V8 BUSINESS PHONE: 604-362-5207 MAIL ADDRESS: STREET 1: 409 GRANVILLE STREET STREET 2: SUITE 1700 CITY: VANCOUVER STATE: A1 ZIP: V6C 1T2 6-K 1 aurora_6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Commission File No. 001-38691 AURORA CANNABIS INC. (Translation of registrant's name into English) 2207 90B St. SW Edmonton, Alberta T6X 1V8 Canada (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F Form 20-F ☐ Form 40-F ☒ SUBMITTED HEREWITH Exhibits Description 99.1 News release dated August 6, 2025 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. AURORA CANNABIS INC. /s/ Miguel Martin Miguel Martin Chief Executive Officer Date: August 6, 2025 EX-99.1 2 ex991.htm NEWS RELEASE DATED AUGUST 6, 2025 Exhibit 99.1 Aurora Cannabis Announces Fiscal 2026 First Quarter Results NASDAQ | TSX: ACB • Expands YoY Global Medical Cannabis Net Revenue 1 by 37% to $64.8 million, while increasing International Medical Cannabis Net Revenue 1 by 85% to $37.1 million • Delivers Adjusted EBITDA 1 growth in excess of 200%, reaching $10.8 million • Generates Positive Free Cash Flow 1 of $9.2 million, representing significant YoY growth of 42% • Maintains Strong Balance Sheet with ~$186.0 million of Cash and Debt-Free Cannabis Business 2 EDMONTON, AB, Aug. 6, 2025 /CNW/ - Aurora Cannabis Inc. (the "Company" or "Aurora" ) (NASDAQ: ACB) (TSX: ACB), a leading Canada-based global medical cannabis company, today announced its financial and operational results for the first quarter 2026 period ending June 30, 2025. "We delivered another strong quarter of sustained, profitable growth, driven by disciplined execution of our strategy. Global medical cannabis net revenue 1 rose 37%, supported by 85% growth in international markets, most notably Germany and Poland, alongside growth in Canadian medical cannabis and record contributions from our plant propagation business. These top-line gains were supported by more than 200% growth in adjusted EBITDA 1 , and 42% growth in positive free cash flow 1 ," said Executive Chairman and Chief Executive Officer Miguel Martin. "Our performance highlights the competitive distinction of our platform. International medical cannabis our highest-margin segment now accounts for 57% of our global medical cannabis net revenue¹. Bevo, our plant propagation business, which diversifies our revenue streams beyond cannabis, added further momentum through seasonal strength and continued organic expansion. And for the second consecutive year, we expect to generate positive annual free cash flow¹, reinforcing our operational execution and differentiation from peers," concluded Mr. Martin. __________________________ 1 This press release includes certain non-GAAP financial measures, which are intended to supple